 | • レポートコード：GIR-107A14554 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、巣状分節性糸球体硬化症薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。巣状分節性糸球体硬化症薬の種類別市場規模（Losmapimod、SHP-627、Sparsentan、TM-5484、その他）、用途別市場規模（クリニック、研究センター、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・巣状分節性糸球体硬化症薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Complexa Inc、Dimerix Bioscience Pty Ltd、GlaxoSmithKline Plc、Retrophin Inc、Takeda、Variant Pharmaceuticals Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：Losmapimod、SHP-627、Sparsentan、TM-5484、その他 ・用途別分析2016年-2026年：クリニック、研究センター、病院、その他 ・巣状分節性糸球体硬化症薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・巣状分節性糸球体硬化症薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・巣状分節性糸球体硬化症薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・巣状分節性糸球体硬化症薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・巣状分節性糸球体硬化症薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Focal Segmental Glomerulosclerosis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Focal Segmental Glomerulosclerosis Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Focal Segmental Glomerulosclerosis Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Focal Segmental Glomerulosclerosis Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Losmapimod
SHP-627
Sparsentan
TM-5484
Others
Market segment by Application can be divided into
Clinic
Research Center
Hospital
Others
The key market players for global Focal Segmental Glomerulosclerosis Drug market are listed below:
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Retrophin Inc
Takeda
Variant Pharmaceuticals Inc
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Focal Segmental Glomerulosclerosis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Focal Segmental Glomerulosclerosis Drug, with price, sales, revenue and global market share of Focal Segmental Glomerulosclerosis Drug from 2019 to 2021.
Chapter 3, the Focal Segmental Glomerulosclerosis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Focal Segmental Glomerulosclerosis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Focal Segmental Glomerulosclerosis Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Focal Segmental Glomerulosclerosis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Focal Segmental Glomerulosclerosis Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Focal Segmental Glomerulosclerosis Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Losmapimod
1.2.3 SHP-627
1.2.4 Sparsentan
1.2.5 TM-5484
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Focal Segmental Glomerulosclerosis Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.3.5 Others
1.4 Global Focal Segmental Glomerulosclerosis Drug Market Size & Forecast
1.4.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Value (2016-2026))
1.4.2 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume (2016-2026)
1.4.3 Global Focal Segmental Glomerulosclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Focal Segmental Glomerulosclerosis Drug Production Capacity Analysis
1.5.1 Global Focal Segmental Glomerulosclerosis Drug Total Production Capacity (2016-2026)
1.5.2 Global Focal Segmental Glomerulosclerosis Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Focal Segmental Glomerulosclerosis Drug Market Drivers
1.6.2 Focal Segmental Glomerulosclerosis Drug Market Restraints
1.6.3 Focal Segmental Glomerulosclerosis Drug Trends Analysis
2 Manufacturers Profiles
2.1 Complexa Inc
2.1.1 Complexa Inc Details
2.1.2 Complexa Inc Major Business
2.1.3 Complexa Inc Focal Segmental Glomerulosclerosis Drug Product and Services
2.1.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Dimerix Bioscience Pty Ltd
2.2.1 Dimerix Bioscience Pty Ltd Details
2.2.2 Dimerix Bioscience Pty Ltd Major Business
2.2.3 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product and Services
2.2.4 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 GlaxoSmithKline Plc
2.3.1 GlaxoSmithKline Plc Details
2.3.2 GlaxoSmithKline Plc Major Business
2.3.3 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product and Services
2.3.4 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Retrophin Inc
2.4.1 Retrophin Inc Details
2.4.2 Retrophin Inc Major Business
2.4.3 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product and Services
2.4.4 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda Focal Segmental Glomerulosclerosis Drug Product and Services
2.5.4 Takeda Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Variant Pharmaceuticals Inc
2.6.1 Variant Pharmaceuticals Inc Details
2.6.2 Variant Pharmaceuticals Inc Major Business
2.6.3 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product and Services
2.6.4 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Focal Segmental Glomerulosclerosis Drug Sales by Manufacturer
3.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Focal Segmental Glomerulosclerosis Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Focal Segmental Glomerulosclerosis Drug Manufacturer Market Share
3.4.2 Top 6 Focal Segmental Glomerulosclerosis Drug Manufacturer Market Share
3.5 Global Focal Segmental Glomerulosclerosis Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Focal Segmental Glomerulosclerosis Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Focal Segmental Glomerulosclerosis Drug Market Size by Region
4.1.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2016-2026)
4.2 North America Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026)
4.3 Europe Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026)
4.4 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026)
4.5 South America Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026)
4.6 Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Type (2016-2026)
5.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2016-2026)
5.3 Global Focal Segmental Glomerulosclerosis Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Focal Segmental Glomerulosclerosis Drug Sales in Volume by Application (2016-2026)
6.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2016-2026)
6.3 Global Focal Segmental Glomerulosclerosis Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2026)
7.2 North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2026)
7.3 North America Focal Segmental Glomerulosclerosis Drug Market Size by Country
7.3.1 North America Focal Segmental Glomerulosclerosis Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2026)
8.2 Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2026)
8.3 Europe Focal Segmental Glomerulosclerosis Drug Market Size by Country
8.3.1 Europe Focal Segmental Glomerulosclerosis Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Market Size by Region
9.3.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2026)
10.2 South America Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2026)
10.3 South America Focal Segmental Glomerulosclerosis Drug Market Size by Country
10.3.1 South America Focal Segmental Glomerulosclerosis Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Focal Segmental Glomerulosclerosis Drug Market Size by Country
11.3.1 Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Focal Segmental Glomerulosclerosis Drug Typical Distributors
12.3 Focal Segmental Glomerulosclerosis Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Complexa Inc Basic Information, Manufacturing Base and Competitors
Table 4. Complexa Inc Major Business
Table 5. Complexa Inc Focal Segmental Glomerulosclerosis Drug Product and Services
Table 6. Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Dimerix Bioscience Pty Ltd Basic Information, Manufacturing Base and Competitors
Table 8. Dimerix Bioscience Pty Ltd Major Business
Table 9. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product and Services
Table 10. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. GlaxoSmithKline Plc Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Plc Major Business
Table 13. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product and Services
Table 14. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Retrophin Inc Basic Information, Manufacturing Base and Competitors
Table 16. Retrophin Inc Major Business
Table 17. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product and Services
Table 18. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Takeda Basic Information, Manufacturing Base and Competitors
Table 20. Takeda Major Business
Table 21. Takeda Focal Segmental Glomerulosclerosis Drug Product and Services
Table 22. Takeda Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Variant Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 24. Variant Pharmaceuticals Inc Major Business
Table 25. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product and Services
Table 26. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Global Focal Segmental Glomerulosclerosis Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 28. Global Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 29. Market Position of Manufacturers in Focal Segmental Glomerulosclerosis Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 30. Global Focal Segmental Glomerulosclerosis Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 31. Head Office and Focal Segmental Glomerulosclerosis Drug Production Site of Key Manufacturer
Table 32. Focal Segmental Glomerulosclerosis Drug New Entrant and Capacity Expansion Plans
Table 33. Focal Segmental Glomerulosclerosis Drug Mergers & Acquisitions in the Past Five Years
Table 34. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 35. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026) & (K Pcs)
Table 36. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 37. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2021-2026) & (USD Million)
Table 38. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 39. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 40. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2016-2021e) & (USD Million)
Table 41. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2021-2026) & (USD Million)
Table 42. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 43. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2021-2026) & (USD/Pcs)
Table 44. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 45. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 46. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2016-2021e) & (USD Million)
Table 47. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2021-2026) & (USD Million)
Table 48. Global Focal Segmental Glomerulosclerosis Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 49. Global Focal Segmental Glomerulosclerosis Drug Price by Application (2021-2026) & (USD/Pcs)
Table 50. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 51. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 52. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 53. North America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 54. North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 55. North America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 56. North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 57. North America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 58. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 59. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 60. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 61. Europe Focal Segmental Glomerulosclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 62. Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 63. Europe Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 64. Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 65. Europe Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 66. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 67. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026) & (K Pcs)
Table 68. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 69. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue by Region (2021-2026) & (USD Million)
Table 70. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 71. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 72. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 73. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 74. South America Focal Segmental Glomerulosclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 75. South America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 76. South America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 77. South America Focal Segmental Glomerulosclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 78. South America Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 79. South America Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 80. South America Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 81. South America Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 82. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 83. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 84. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 85. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 86. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 87. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 88. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 89. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Focal Segmental Glomerulosclerosis Drug Typical Distributors
Table 93. Focal Segmental Glomerulosclerosis Drug Typical Customers
List of Figures
Figure 1. Focal Segmental Glomerulosclerosis Drug Picture
Figure 2. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type in 2020
Figure 3. Losmapimod
Figure 4. SHP-627
Figure 5. Sparsentan
Figure 6. TM-5484
Figure 7. Others
Figure 8. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application in 2020
Figure 9. Clinic
Figure 10. Research Center
Figure 11. Hospital
Figure 12. Others
Figure 13. Global Focal Segmental Glomerulosclerosis Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Focal Segmental Glomerulosclerosis Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Focal Segmental Glomerulosclerosis Drug Sales (2016-2026) & (K Pcs)
Figure 16. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Focal Segmental Glomerulosclerosis Drug Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Focal Segmental Glomerulosclerosis Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Focal Segmental Glomerulosclerosis Drug Market Drivers
Figure 20. Focal Segmental Glomerulosclerosis Drug Market Restraints
Figure 21. Focal Segmental Glomerulosclerosis Drug Market Trends
Figure 22. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Manufacturer in 2020
Figure 23. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Manufacturer in 2020
Figure 24. Focal Segmental Glomerulosclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Focal Segmental Glomerulosclerosis Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Focal Segmental Glomerulosclerosis Drug Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2016-2026)
Figure 28. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2016-2026)
Figure 29. North America Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 30. Europe Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 32. South America Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 34. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2016-2026)
Figure 35. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2016-2026)
Figure 36. Global Focal Segmental Glomerulosclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 38. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2016-2026)
Figure 39. Global Focal Segmental Glomerulosclerosis Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2016-2026)
Figure 41. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 42. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2016-2026)
Figure 43. North America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 44. United States Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2016-2026)
Figure 48. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 49. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2016-2026)
Figure 50. Europe Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 51. Germany Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2016-2026)
Figure 60. China Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2016-2026)
Figure 67. South America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 68. South America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2016-2026)
Figure 69. South America Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Focal Segmental Glomerulosclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
世界のドルテグラビル/リルピビリン併用薬市場 2021：企業別、地域別、種類・用途別 The Dolutegravir/Rilpivirine Combination Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…- 世界のスニチニブ薬市場 2021：企業別、地域別、種類・用途別 The Sunitinib Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…
- 世界のシャルコー・マリー・トゥース病I型A型治療薬市場 2021：企業別、地域別、種類・用途別 The Charcot-Marie-Tooth Disease Type I A Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- 世界のアンブリセンタン薬市場 2021：企業別、地域別、種類・用途別 The Ambrisentan Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…
- 世界の退形成性乏突起星細胞腫治療薬市場 2021：企業別、地域別、種類・用途別 The Anaplastic Oligoastrocytoma Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…